Chromium (Cr) is commonly used as a complementary medicine for diabetes mellitus. Several studies suggest that Cr intakes may improve glucose metabolism and decrease oxidative stress. Therefore, we aimed to assess the effects of chromium histidinate (CrHis) supplementation using a range of reliable biomarkers of oxidative damage and histopathological changes in rats with diabetic retinopathy. Diabetes was induced with streptozotocin [(STZ), 55 mg/kg] by intraperitoneal injection in male Long-Evans rats. Three weeks after STZ injection, rats were divided into four groups, namely, untreated normal controls, normal rats receiving CrHis (110 μg/kg/day); untreated diabetics and diabetics treated with CrHis (110 μg/kg/day) orally for 12 weeks. In the untreated diabetic group, levels of serum glucose, glycosylated haemoglobin (HbA1c), total cholesterol (TC) and retina malondialdehyde (MDA) were significantly increased, while expressions of retina insulin, and glucose transporter 1 (GLUT 1) and glucose transporter 3 (GLUT3) and level of serum insulin were decreased. CrHis supplementation was found to reduce the levels of glucose, HbA1c, total cholesterol and MDA and to improve the GLUT1, GLUT3 and insulin expressions in STZ-induced diabetic rats. CrHis prevents the changes in the expressions of GLUT1, GLUT3 and insulin and the level of MDA in the retina tissue, confirming the protective effect of CrHis supplementation against the retinopathy caused by STZ. Histopathologic findings suggest that the CrHis-treated diabetic group had normal retinal tissue appearance compared with the untreated diabetic group. These results verify that CrHis has critical beneficial effects against retinal complications. Although detailed studies are required for the evaluation of the exact mechanism of the ameliorative effects of CrHis against diabetic complications, these preliminary experimental findings demonstrate that CrHis exhibits antidiabetic effects in a rat model of diabetic retinopathy by regulating the glucose metabolism and suppressing retinal tissue damage.
18 December 2015 in Hormone Molecular Biology and Clinical Investigation
Acylated ghrelin (AG) effect on GnRH secretion is mediated, at least in part, by GH secreta-gogue receptor (GHS-R) which is present in the GnRH neurons. As the acylation is mandatory for binding to GHS-R, unacylated isoform of ghrelin (UAG) action on gonadotropin secretion is likely to be mediated by other receptors or mediators that have not been identified yet. UAG, therefore, may act partially via a GHS-R-independent mechanism and inhibitory impact of UAG on GnRH neurons may be executed via modulation of other neuronal networks. Ghrelin and gonadotropin inhibitory hormone (GnIH), two agonistic peptides, have been known as important regulators of reproductive events. Potential impact of ghrelin on the activity of GnIH neurons is not exactly known. Both GnIH and ghrelin are potent stimulators of food intake and inhibitors of gonadotropin release. By binding G-protein coupled GnIH receptor (GnIH-R), GPR147, which is located in the human gonadotropes and GnRh neurons, GnIH exerts an inhibitory effect on both GnRH neurons and the gonadotropes. The GnIH-GPR147 system receives information regarding the status of energy reservoir of body from circulating peptides and then transfers them to the kisspeptin-GnIH-GnRH network. Due to wide distribution of this network in brain GnIH neurons may project on ghrelin neurons in the arcuate nucleus and contribute to the regulation of UAG’s central effects or vice versa. Together, the unidentified ghrelin receptor in the hypothalamus and hypophysis may be GnIH-R. Therefore, it is reasonable that ghrelin may act on both hypothalamus and hypophysis via GnIH-GPR147 system to block gonadotropin synthesis and secretion.
In brain ischaemia (BI), the oxidative and ionic stresses lead slowly but definitely to the injury of neurones. The present investigation is looking to check the status of certain oxidative stress markers and trace elements which are induced in response to brain ischaemia with sodium valproate (VPA), a neuroprotective agent, in the rats exposed to the model of BI. Although VPA is already used for clinical purposes, it deserves careful examination of the potentially detrimental effects of VPA in conditions of ischaemia closely linked to hepatotoxicity and thrombocytopenia. Forty rats were randomly assigned into five groups (n = 8 per group): Control, Sham, Brain Ischaemia (BI), BI + Valproic Acid (VPA), and VPA only. Ischaemia was induced in the BI and BI + VPA groups by bilateral occlusion of the common carotid arteries for 30 min. VPA was administered orally at a dose of 100 mg/kg daily for seven days in the BI + VPA and VPA-only groups. This dose was based on previous preclinical safety and efficacy data. Control, Sham, and BI groups received saline. The Sham group underwent surgical procedures without carotid occlusion. The biochemical investigations pertaining to cortical tissue demonstrated the fact that BI has decreased all antioxidant enzyme levels of SOD, CAT, GPx, and those of trace elements such as Mg, Zn, and Se. At the same time, malondialdehyde (MDA) and neurotoxic metals (Cr, Fe, Cu) increased. These changes brought by BI were restored through treatment with VPA on oxidative stress and the restoration of trace element balance along with reductions in those associated with oxidative damage. The results thus reinforce the capacity of VPA for neuroprotective benefits against ischaemic damage inflicted within brain tissue and hence merit the further exploration of the mechanistic action of this therapeutic A.
Objectives: This study was aimed to investigate the diagnostic values of serum levels of asprosin and neutrophil gelatinase-associated lipocalin (NGAL) in Retinopathy of prematurity (ROP) and to assess the role of these biomarkers on the development and progression of the condition. Methods: This study was carried out from April 2020 to February 2021 in the department of ophthalmology of a tertiary hospital in Turkey. Thirty patients diagnosed with ROP and 30 healthy newborns were included the study. Serum NGAL and asprosin levels were determined via ELISA. Results: The median serum NGAL levels were found to be similar between the ROP group and the control group (p=0.595). Median asprosin levels were significantly higher in patients diagnosed with ROP [46.58 (12.70–142.28) ng/mL] compared to healthy subjects [13.05 (10.92–17.73) ng/mL] (p=0.001). The optimal cut-off value of asprosin by ROC analysis was 30 ng/mL (AUC: 0.754, p=0.001) for diagnosing ROP. Serum asprosin levels were positively correlated with serum ALP levels and inversely correlated with gestational week, uric acid and AST values (all, p<0.005). Conclusions: Our results demonstrated that asprosin, but not NGAL, could be a biomarker for the diagnosis of ROP.
1 January 2019 in Journal of the chemical society of pakistan
Journal of the Chemical Society of Pakistan (JCSP) is a bimonthly Journal which publishes results of original, unpublished research work and review articles in all fields of Chemistry.
DM is a common, chronic metabolic disease and have harmful effect of many diverse tissue including testis. One of the way leads tissue damage is the modification of Trpm2 channels by increased reactive oxygen species (ROS). For the first time, we were aimed to investigate TRPM2 channel activation in diabetic rats testes and to examine the efficacy of NAC treatment. In our study, 28 male rats were used and animals were divided into 4 groups; Control , NAC , DM , DM + NAC. The experimental phase was designed as 8 weeks. MDA level which is an indicator for lipid peroxidation, was measured by spectrophotometric method. Tunel assay was used to determined apoptosis on testicular tissue. TRPM2 immune reactivity was determined by Avidin-Biotin-Peroxidase Complex method and QPCR used to TRPM2 expression levels. It was seen MDA levels were significantly increased in DM and decrease after NAC treatment. Similarly, it was observed that apoptosis levels, which increased highly significantly in diabetic rats, decreased to the levels of the control group after treatment. TRPM2 activation and expression levels were significantly lower in DM group. Our data contradict previous studies in other tissues in diabetics. It may due to the experiment duration.